Fulcrum Therapeutics price target raised to $10 from $7 at RBC Capital

RBC Capital raised the firm’s price target on Fulcrum Therapeutics (FULC) to $10 from $7 and keeps a Sector Perform rating on the shares. The company presented first look at the 20 mg dose cohort of Phase 1b PIONEER trial at ASH, and while the data are still maturing, the 9.9% HbF boost compares favorably to the 5.6%/8.6% shown by the 12 mg dose, the analyst tells investors in a research note.